Cambridge Nutritional Sciences (FRA:RVKA) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cambridge Nutritional Sciences 5-Year Yield-on-Cost %?

Cambridge Nutritional Sciences FRA:RVKA 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. The stock has 3 warning signs investors should review. Among 323 Medical Devices & Instruments companies, Cambridge Nutritional Sciences ranks worse than 309597.21% on this metric.

Cambridge Nutritional Sciences's yield on cost for the quarter that ended in Sep. 2025 was 0.00.


The historical rank and industry rank for Cambridge Nutritional Sciences's 5-Year Yield-on-Cost % or its related term are showing as below:



FRA:RVKA's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.42
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Cambridge Nutritional Sciences  (FRA:RVKA) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Cambridge Nutritional Sciences 5-Year Yield-on-Cost % Related Terms


FRA:RVKA vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison

For the Medical Instruments & Supplies subindustry, Cambridge Nutritional Sciences's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cambridge Nutritional Sciences 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cambridge Nutritional Sciences's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Cambridge Nutritional Sciences's 5-Year Yield-on-Cost % falls into.



Cambridge Nutritional Sciences 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Cambridge Nutritional Sciences is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Cambridge Nutritional Sciences (FRA:RVKA) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 22, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cambridge Nutritional Sciences and its competitors. According to the industry distribution chart, Cambridge Nutritional Sciences ranks #999999 out of 323 companies in the Medical Devices & Instruments industry.
Is Cambridge Nutritional Sciences' 5-Year Yield-on-Cost % too high?
Cambridge Nutritional Sciences' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Cambridge Nutritional Sciences ranks #999999 out of 323 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Cambridge Nutritional Sciences' 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Cambridge Nutritional Sciences ranks #999999 out of 323 companies for 5-Year Yield-on-Cost %. This places Cambridge Nutritional Sciences in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.42, based on 323 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Cambridge Nutritional Sciences and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Nutritional Sciences's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (FRA:RVKA) is currently considered Possible Value Trap. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 30% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Cambridge Nutritional Sciences (FRA:RVKA), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambridge Nutritional Sciences Business Description

Other Exchanges CNSL:UK
Address One Fleet Place, London, GBR, EC4M 7WS
Cambridge Nutritional Sciences PLC is a medical diagnostics company specializing in the development, manufacture, and distribution of food sensitivity test kits. Its product portfolio includes tests designed to detect immune reactions to various foods, helping healthcare professionals and patients identify dietary and lifestyle changes to improve long-term health and wellbeing. The company operates in the United Kingdom and serves the customer base across various countries through laboratories and healthcare providers. It generates revenue by selling diagnostic kits and providing clinical analysis services centered on food sensitivity and gut health. The group has two reportable segments: Health and Nutrition; and Corporate. The Health and Nutrition segment generates majority revenue.